stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Net income
Ligand Pharmaceuticals Incorporated's net income for fiscal 2025 was $124.5M, compared with −$4.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $51.5M. Over the past ten years it has ranged from −$33.4M (fiscal 2022) to $629.3M (fiscal 2019); the current reading is higher than 73% of that period. Ligand Pharmaceuticals Incorporated ranks 37th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $124.5M | — |
| FY2024 | −$4.0M | — |
| FY2023 | $52.2M | — |
| FY2022 | −$33.4M | — |
| FY2021 | $57.1M | — |
| FY2020 | −$3.0M | — |
| FY2019 | $629.3M | 339.09% |
| FY2018 | $143.3M | 1,041.45% |
| FY2017 | $12.6M | — |
| FY2016 | −$1.6M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$28.5M | — |
| Jun 2026 | $48.5M | — |
| Mar 2026 | −$13.3M | — |
| Dec 2025 | $44.8M | (61.81%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated | $51.5M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$77.6M |
| PTCT PTC Therapeutics, Inc. compare | −$106.0M |
| ORKA Oruka Therapeutics, Inc. compare | −$132.9M |
| CGON CG Oncology, Inc. compare | −$224.4M |
| KOD Kodiak Sciences Inc. compare | −$242.0M |
| IMVT Immunovant, Inc. compare | −$538.2M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$565.2M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$903.9M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on LGND
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement